Pharmaceutical Industry Blog

Last Updated: September 3, 2026 TL;DR: Gabon answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with no list at all. The new Agence Nationale du Médicament et des Autres Produits de Santé, created by ordinance in October 2023 and given its statutes in January 2025, publishes a single dossier checklist for the Autorisation de Mise sur le Marché Gabonais and no reliance or abridged pathway; its guidelines

Last Updated: September 3, 2026 TL;DR: The Gambia answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three lists at three layers, and India appears on none of them by name. The Medicines Control Agency's 2023 reliance policy names the EMA, the EU and EEA authorities, the MHRA, the US FDA, PMDA, Swissmedic, Health Canada, the TGA, WHO prequalification, AVAREF, ECOWAS and PIC/S, plus any authority the

Last Updated: September 2, 2026 TL;DR: Jamaica answers the question we always ask first — is there a list of regulators the country relies on, and is India on it — in a way no market in this series has quite matched: the regulation has no list, the procurement agency has one, and the regional reliance mechanism has another. The Food and Drugs Regulations of 1975 contain no reliance or abridged pathway at all; a new drug needs a certificate from the competent authority of the

Last Updated: September 2, 2026 TL;DR: Armenia is the first market in this series where the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — has to be answered twice, once nationally and once for the Eurasian Economic Union. Nationally, the simplified 31-day route under the Law on Medicines is keyed to products registered by a member country of the ICH or PIC/S, or prequalified by the WHO. India's CDSCO is an ICH

Last Updated: September 1, 2026 TL;DR: Moldova gives the clearest answer this series has produced to the question we always ask first, and the answer is unfavourable but precise, which is worth more than a vague encouragement. Legea nr. 153 of 19 June 2025 defines in its own first article the countries it treats as having the same level of requirements for proving quality, safety and efficacy: the European Economic Area states, the United States, the United Kingdom, Switzerla

Last Updated: September 1, 2026 TL;DR: Namibia does not fit either pattern this series has been finding. It is not a market with a closed reference-country list that excludes India, and it is not a market with no list at all. The gazetted regulation creates the recognition hook in deliberately open language — registration granted by “other medicines regulatory authorities recognised by the Council” — and names nobody. The Council's actual list of recognised authorities lives